After results from a recent trial demonstrated its efficacy, the FDA expanded the indication of a cancer drug to include adult patients with chronic graft versus host disease who do not respond to other...
The FDA has granted accelerated approval to linvoseltamab-gcpt, a BCMA-directed bispecific T-cell engager, offering a new option for patients with heavily pretreated relapsed or refractory multiple myeloma....
